---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-019752"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-06-01T23:59:59+00:00"
generated_at: "2026-06-14T09:24:09.056179+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem reports Q1 preliminary: Phexxi sales up 35% to $5.8M, operating loss down 85%

## Summary
- Net product sales of Phexxi rose >35% to ~$5.8M in Q1 2023 from $4.3M in Q1 2022.
- Total operating expenses cut >70% to ~$9.4M vs $33.2M in prior-year quarter.
- Loss from operations decreased >85% to ~$3.6M from $28.9M a year ago.
- Company on track for quarterly EBITDA breakeven by year-end 2023.
- Regained compliance with debt covenants via May 18 reverse stock split.

## SEC filing metadata
- accession: 0001493152-23-019752
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-06-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/0001493152-23-019752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-019752
- JSON: https://secwatch.observer/filing/0001493152-23-019752.json
- Plain text: https://secwatch.observer/filing/0001493152-23-019752.txt

## Key facts
- Earnings Releases
  Evofem Biosciences, Inc. reported the first quarter of 2023 results: revenue approximately $5.8 million. Guidance reaffirmed.
  - Period: the first quarter of 2023
  - Revenue: approximately $5.8 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: hormone-free prescription contraceptive gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) . ● Increased Phexxi net product sales more than 35% to approximately $5.8 million in Q1 2023, versus $4.3 million in Q1 2022. ● Reduced total operating expenses more than 70% to approximately $9.4 million, versus $33.2 million in Q1 2022. ● Decreased loss
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/0001493152-23-019752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.